Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 11/20 | 1.00 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.72 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3132030 | 0.91 | ALOX5 (0.83) | ALOX5LTB4RLTB4R2PTGS1PTGS2 | |
| SCHEMBL8652025 | 0.87 | ALOX5 (0.76) | ALOX5LTB4RLTB4R2PTGS1PTGS2 | |
| SCHEMBL2353230 | 0.87 | ALOX5 (0.76) | ALOX5LTB4RLTB4R2PTGS1PTGS2 | |
| SCHEMBL10691196 | 0.85 | ALOX5 (0.74) | ALOX5LTB4RLTB4R2PTGS1PTGS2 | |
| SCHEMBL10689449 | 0.85 | ALOX5 (1.00) | ALOX5LTB4RLTB4R2PTGS1PTGS2 | |
| SCHEMBL8387473 | 0.85 | ALOX5 (0.74) | ALOX5LTB4RLTB4R2PTGS1PTGS2 | |
| SCHEMBL2948755 | 0.85 | ALOX5 (0.72) | ALOX5LTB4RLTB4R2 | |
| SCHEMBL10692791 | 0.84 | ALOX5 (1.00) | ALOX5LTB4RLTB4R2PTGS1PTGS2 | |
| Iodomethane SCHEMBL8389381 | 0.82 | ALOX5 (0.70) | ALOX5LTB4RLTB4R2PTGS1PTGS2 | |
| SCHEMBL10693993 | 0.82 | ALOX5 (1.00) | ALOX5LTB4RLTB4R2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090060905-A1 | Use of 15-Lipoxygenase Inhibitors for Treating Obesity | GENFIT (FR) | 2009-03-05 | — | — | US | claimed |
| EP-0196674-A2 | Hydroxamates as modulators of arachidonic acid metabolic pathways | USV PHARMACEUTICAL CORPORATION (US) | 1986-10-08 | — | — | EP | claimed |
| WO-2012001628-A1 | PHOTOELECTRIC CONVERSION DEVICE COMPRISING HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF AS ADDITIVE AND PROCESS FOR PRODUCING SAME | BASF SE (DE) | 2012-01-05 | — | — | WO | disclosed |
| US-20120000533-A1 | PHOTOELECTRIC CONVERSION DEVICE COMPRISING HYDROXAMIC ACID OR A SALT THEREOF AS ADDITIVE AND PROCESS FOR PRODUCING SAME | BASF SE (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120000533-A1 | PHOTOELECTRIC CONVERSION DEVICE COMPRISING HYDROXAMIC ACID OR A SALT THEREOF AS ADDITIVE AND PROCESS FOR PRODUCING SAME | BASF SE (DE) | 2012-01-05 | — | — | US | disclosed |
| US-4792560-A | ANTIALLERGENS; ANTIINFLAMMATORY AGENTS | RORER PHARMACEUTICAL CORPORATION (US) | 1988-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060905-A1 | Use of 15-Lipoxygenase Inhibitors for Treating Obesity | ALOX15, ALOX15B, ALOX12 | ALOX5 4/4885LTB4R 35/4885LTB4R2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.